Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerburg Wulf

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Cancer Research|May 3, 2014
Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancerMan-Li Luo, Chang Gong, Chun-Hau Chen, et al.
Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
EMBO Molecular Medicine|May 14, 2025
Targeting transcription factors through an IMiD independent zinc finger domainBee Hui Liu, Miao Liu, Sridhar Radhakrishnan, et al.
Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Cancer Research|May 3, 2014
Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancerMan-Li Luo, Chang Gong, Chun-Hau Chen, et al.
Nature Communications|January 6, 2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trialMrinal Gounder, Melissa Johnson, Rebecca S Heist, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in <i>PALB2</i> or Somatic Mutations in <i>BRCA1</i> or <i>BRCA2</i>Nadine M Tung, Mark E Robson, Tianyu Li, et al.
JAMA Oncology|September 4, 2020
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical TrialSara M Tolaney, Romualdo Barroso-Sousa, Tanya Keenan, et al.
EMBO Molecular Medicine|May 14, 2025
Targeting transcription factors through an IMiD independent zinc finger domainBee Hui Liu, Miao Liu, Sridhar Radhakrishnan, et al.
Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.
Pageof 3